Ursula Theuretzbacher published numerous articles in national
and international journals.
Some examples:
| Reviews, leading articles |
| • |
U. Theuretzbacher: Accelerating resistance, inadequate antibacterial
pipelines and international responses. IJAA 2011, December, in press |
| • |
Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D,
Theuretzbacher U.:
Protein
binding - do we ever learn? Antimicrob Agents Chemother. 2011
May 2 |
| • |
Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H.:
The
Effect of Critical Illness on Drug Distribution. Curr Pharm Biotechnol.
2011 May 10 |
| • |
Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, Macgowan
A, Theuretzbacher U, Turnidge J.:
Conserving
antibiotics for the future: New ways to use old and new drugs
from a pharmacokinetic and pharmacodynamic perspective.
Drug Resist Updat. 2011, 14:107-117. |
| • |
Y. Li, U. Theuretzbacher, CJ. Clancy, MH. Nguyen,
H. Derendorf: Pharmacokinetic/Pharmacodynamic
Profile of Posaconazole. Clin Pharmacokin 2010, 49 (6) 379-396 |
| • |
U. Theuretzbacher: Antibiotics:
derivative drugs, novel compounds and the need for effective resistance
strategies.
Future Microbiol. 2009 Dec;4:1243-7 |
| • |
U. Theuretzbacher: Antibiotic
innovation on the horizon?
APUA news 2009, 27, 1 & 2 |
| • |
U. Theuretzbacher: Future
antibiotics scenarios: is the tide starting to turn?
International Journal of Antimicrobial Agents 2009; 34:15-20 |
| • |
J. Mouton, U. Theuretzbacher, W. Craig, P. Tulkens, H. Derendorf,
O. Cars: Tissue-concentrations:
Do we ever learn?
J Antimicrob Chemother. 2008;61(2):235-7 |
| • |
U. Theuretzbacher: Tissue
penetration of antibacterial agents: how should this be incorporated
into pharmacodynamic analyses? (Abstract,
page
1)
Current Opinion in Pharmacology 2007; 7/5:498-504 |
| • |
U. Theuretzbacher: Antimicrobial Resistance--2006
Annual Conference. Science-prevention-control. IDrugs. 2006 Sep;9(9):622-4 |
| • |
U. Theuretzbacher: The opponent, we were unable to defeat. Beta-lactamases.
Pharm.unserer Zeit 5/2006 (35): 416-21
Page
1 |
| • |
U. Theuretzbacher, F. Ihle, H. Derendorf: Pharmacokinetic/Pharmacodynamic
Profile of Voriconazole. Clin Pharmacokinet 2006; 45 (7): 649-663
(Abstract) |
| • |
U. Theuretzbacher, J. Toney: Nature's
clarion call of antibacterial resistance: are we listening?
Curr Opin Investig Drugs. 2006 Feb;7(2):158-66. (Abstract) |
| • |
U. Theuretzbacher: Pharmacokinetics/Phamacodynamics
of Echinocandins. European Journal of Clinical Microbiology
and Infectious Diseases 2004, published online: 14 October 2004
|
| • |
U. Theuretzbacher: Beta-Lactamases
and Beta-Lactamase Inhibitors - an update. Chemotherapie-Journal
2004 (13) 5 |
| • |
U. Theuretzbacher: Cefpodoxim
bei Atemwegsinfektionen. Antibiotika Monitor 2000, (16) 4 |
| • |
U. Theuretzbacher: ß-Laktamasen und ß-Laktamase-Inhibitoren.
Chemotherapie-Journal 1998 (7) 4: 136-142 |
| • |
U. Theuretzbacher: Erreger der Otitis media. Chemotherapie-Journal
1997 (6) Suppl. 16: 17-14 |
| • |
U. Theuretzbacher: Neue orale Cephalosporine. Antibiotika Monitor
1997 (12) 2: 31-37 |
| • |
U. Theuretzbacher: Therapie der Wahl bei eitriger Angina. Arzneimittelpraxis
1997 (27) 1 |
| • |
F. Vogel, U. Theuretzbacher: Antibiotikatherapie auf der Intensivstation.
Intensivmed. 1997 (34): 14-23 |
| • |
U. Theuretzbacher: Antibiotikatherapie der A-Streptokokken-Pharyngotonsillitis.
Antibiotika Monitor 1997 (12) 2: 26-30 |
| • |
U. Theuretzbacher: Alte
und neue Infektionskrankheiten. 1996 (4) Medizin im Dialog |
| • |
U. Theuretzbacher: Makrolide. 1995, (11) 3: 26-37 |
| • |
U. Theuretzbacher: Resistenzprobleme im Krankenhaus. Österreichische
Krankenhaus Pharmazie. 1995 (9), 4: 8-10 |
| • |
U. Theuretzbacher: Penicillin-resistente Pneumokokken. 1994, (10)
3: 76-81 |
| |
F. Vogel, U. Theuretzbacher: Makrolide. MMW 1994 (136):771-776 |
Articles, abstracts |
| • |
Margret Seewald, Ursula Theuretzbacher: Schneller
Erregernachweis bei Vaginalinfektionen. Geburtshilfe und Frauenheilkunde
2001, 61: 1-4 |
| • |
M. Seewald, U. Theuretzbacher: In-vitro activity of piperacillin
alone and combined with sulbactam or tazobactam against hospital-derived
pathogens. ECCMID 2000, abstract |
| • |
M. Seewald, U. Theuretzbacher: Evaluation of BD Affirm VP III microbial
identification test for three vaginal pathogens. Third symposium on
molecular diagnostics in laboratory medicine, Graz, 2000, abstract |
| • |
Kurt
Naber, Ursula Theuretzbacher, G. Moneva-Koucheva, H. Staß:
Urinary excretion and bactericidal activity of intravenous ciprofloxacin
compared with oral ciprofloxacin. European Journal of Microbiology
and Infectious Diseases 1999, 18: 783-789 |
| • |
F. Allerberger, I. Klare, U. Theuretzbacher: In vitro-Aktivität
von Fosfomycin gegen vancomycinresistente Enterokokken. Antibiotika
Monitor 1998, XIV/5: 74-79 |
| • |
Kurt
Naber, Ursula Theuretzbacher, Martina Kinzig, Orlin Savov, Fritz Sörgel:
Urinary excretion and bactericidal activity following a single oral
dose of 400mg fleroxacin versus 800mg pefloxacin in healthy volunteers.
Antimicrobial Agents and Chemotherapy 1998, 42: 1659-1665 |
| • |
A. Georgopoulos, U. Theuretzbacher, A. Buxbaum, U. Straschil, W.
Graninger: Susceptibility of community-acquired lower respiratory
tract pathogens: the Alexander Project in Austria. International Conference
on the Macrolides, Azalides, Streptogramins and Ketolides IV 1998,
abstract 11.25 |
| • |
S.
F. Egger, V. Huber-Spitzy, U. Theuretzbacher, M. Schiffbänker
und G. Grabner: Reduction of risk-factors for postoperative infections:
prospective study on 200 cataract-patients
Spektrum der Augenheilkunde, 1994, 8: 265-267 |
Numerous articles in medical weekly journals and newspapers.
